



Living Cell Technologies Limited Company Announcement

LCT granted E.U. Patent for tissue engineering

28 February 2012 – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today received formal notification that it has been granted E.U. Patent No. 1,438,395 from the European Patent Office (EPO). The patent protects the ability to culture two different types of cells derived from Auckland Island pigs, therefore enabling the assembly and maintenance of a mix of cells or artificial tissue in culture for xenotransplantation therapies. The patent expires on 27 September 2022.

Professor Bob Elliott, LCT's Medical Director said, "Whilst we have successfully taken single cell animal transplant treatments into the clinic, a number of chronic disease states could benefit from transplantation of a mix of cells or artificial tissue that work together to ensure survival and appropriate function."

The patent will be assigned to Diatranz Otsuka Limited (DOL), a joint venture company established by LCT and Otsuka Pharmaceutical Factory, Inc. to commercialise xenotransplantation for the treatment of Type 1 diabetes. LCT has a 50 per cent shareholding in DOL, and a service agreement to supply research and development and administrative services to the joint venture. Under the Services and Products agreement, DOL will supply pig cells to LCT for use in developing new xenotransplantation treatments in non-diabetes related disease areas, including neurodegenerative disorders.

Dr Andrea Grant, LCT's CEO, said, "This patent adds to a still growing portfolio of intellectual property and protects future product development opportunities in a range of chronic diseases, particularly those requiring transplantation of a mix of cells or artificially engineered tissues. This patent award means we are well poised to take full advantage of developments in the fields of cell and tissue engineering in our animal transplantation platform."

- Ends -

About Living Cell Technologies

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company holds 50% of Diatranz Otsuka Limited which owns a bio-certified pig herd that it uses as a source of cells and DIABECCELL® which is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. Using breakthrough proprietary microencapsulation technology, IMMUPEL™, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, stroke, and hearing loss. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

For further information: www.lctglobal.com

<p>At the company:</p> <p>Andrea Grant, Chief Executive</p> <p>Tel: +64 9 276 2690</p> <p>Mobile: +64 21 0785 421</p> <p>agrant@lctglobal.com</p>	<p>Media and investor enquiries:</p> <p>Sally Raudon</p> <p>Botica Butler Raudon Partners</p> <p>Tel: +64 9 303 3862</p> <p>Mobile: +64 21 402 502</p> <p>sallyr@botica.co.nz</p>
--	---

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.